Picture of Puretech Health logo

PRTC Puretech Health Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m-6.64%
3m-7.08%
6m+7.9%
1yr-16.71%
Volume Change (%)
10d/3m+11.31%
Price vs... (%)
52w High-12.37%
50d MA-5.17%
200d MA+7.57%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-13.14%
Return on Equity-13.06%
Operating Margin-2534.89%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Puretech Health EPS forecast chart

Profile Summary

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 8th, 2015
Public Since
June 19th, 2015
No. of Employees
90
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
270,859,250

PRTC Share Price Performance

Upcoming Events for PRTC

Half Year 2024 PureTech Health PLC Earnings Release

Similar to PRTC

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

Picture of Batm Advanced Communications logo

Batm Advanced Communications

gb flag iconLondon Stock Exchange

FAQ